Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
0.9849
-0.0751 (-7.08%)
Mar 31, 2025, 1:17 PM EDT - Market open
Pyxis Oncology Revenue
In the year 2024, Pyxis Oncology had annual revenue of $16.15M.
Revenue (ttm)
$16.15M
Revenue Growth
n/a
P/S Ratio
3.84
Revenue / Employee
$366,955
Employees
44
Market Cap
60.66M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
PYXS News
- 5 days ago - Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025 - GlobeNewsWire
- 13 days ago - Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer - GlobeNewsWire
- 7 weeks ago - Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial - GlobeNewsWire
- 3 months ago - Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201 - GlobeNewsWire
- 4 months ago - Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead - Seeking Alpha
- 4 months ago - Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns - Benzinga